ExPEC10V
| Vaccine description | |
|---|---|
| Target | Escherichia coli |
| Vaccine type | Conjugate |
| Clinical data | |
| Other names | ExPEC10-V; ExPEC-10V; ExPECV10; ExPEC-V10; VAC-52416; VAC52416; JNJ-69968054; JNJ69968054 |
| Routes of administration | Intramuscular injection |
ExPEC10V, also known as VAC-52416 or JNJ-69968054, is a vaccine against Escherichia coli infection.[1][2] It is an Escherichia coli polysaccharide conjugate vaccine.[1][2] The vaccine is administered by intramuscular injection.[1] It is being developed by Janssen Pharmaceuticals.[1] As of April 2023, ExPEC10V is in phase 3 clinical trials.[1] It is under development towards approval in the United States, Europe, and Japan.[1] The vaccine is a 10-valent form of the earlier ExPEC4V.[2]
See also
References
- ^ a b c d e f "VAC 52416". AdisInsight. 28 April 2023. Retrieved 28 February 2025.
- ^ a b c Doiron RC, Cotechini T, Nickel JC (June 2024). "It's Time to Embrace Vaccination as We Enter the Postantibiotic Era of Recurrent Urinary Tract Infection Management". The Journal of Urology. 211 (6): 797–799. doi:10.1097/JU.0000000000003969. PMID 38704743.
